Parkinson’s drug trial authorized by the Medicines Agency of Sweden
Musculoskeletal disorders are injuries or pain in the human musculoskeletal system, including the joints, ligaments, muscles, nerves, tendons, and structures that support limbs, neck and back.
The Medicines Agency of Sweden has authorized a Phase I-II clinical study for the investigation of cerebral dopamine neurotrophic factor (CDNF) and Renishaw’s (UK) chronic drug delivery system as a treatment for Parkinson’s disease (PD). The study will follow a randomized, placebo-controlled procedure and is looking to recruit a total of 18 patients with PD. Recruitment of patients will start at the Karolinska University Hospital (Stockholm, Sweden), followed by two other university hospitals. Paul Skinner, General Manager for Renishaw’s Neurological Products Division, said: “This is an important step forward in the use of the Renishaw drug delivery system, and in...
